Abstract
The hepatitis C virus (HCV) belongs to Flaviviridae family and causes hazardous liver diseases leading frequently to cirrhosis and hepatocellular carcinoma. HCV is able to rapidly acquire drug resistance and for this reason there is currently no effective anti-HCV therapy in spite of appearance of new potential drugs. Mathematical models are relevant to predict the efficacy of potential drugs against virus or host targets. One of the promising targets for development of new drugs is the viral NS3 protease. Here we developed a stochastic model of the subgenomic HCV replicon replication in Huh-7 cells and in the presence of the NS3 protease inhibitors. Along with consideration of the stochastic nature of the subgenomic HCV replicon replication, the model takes into account the existence and generation of main NS3 protease drug resistant mutants, namely BILN-2061 (A156T, D168V, R155Q), VX-950 (A156S, A156T, T54A) and SCH-503034 (A156T, A156S, T54A). The model reproduces well the viral RNA kinetics in the cell from the moment of the subgenomic HCV replicon transfection to steady state, as well as the viral RNA suppression kinetics in the presence of NS3 protease inhibitors BILN-2061, VX-950 and SCH-503034. We showed that the resistant mutants should be taken into account for the correct description of biphasic kinetics of the viral RNA suppression. The mutants selected in the presence of different inhibitor concentrations have maximal replication capacity in the given inhibitor concentration range. Our model can be used to interpret the results of the new anti-HCV drug testing in replicon systems, as well as to predict the efficacy of new potential drugs and optimize the mode of their use.
Similar content being viewed by others
References
J. G. O’Leary and G. L. Davis, Therap. Adv. Gastroenterol. 3, 43 (2010).
J. de Bruijne, J. van de Wetering de Rooij, A. A. Van Vliet, et al., Antimicrob Agents Chemother. 56, 4525 (2012).
D. M. Hotho, J. de Bruijne, A. M. O’Farrell, et al., Antivir. Ther. 17, 365 (2012).
O. Lenz, L. Vijgen, J. M. Berke, et al., J. Hepatol. 58, 445 (2013).
M. H. Powdrill, E. P. Tchesnokov, R. A. Kozak, et al., Proc. Natl. Acad. Sci. USA 108, 20509 (2011).
V. Lohmann, V. Lohmann, F. Korner, et al., Science 285, 110 (1999).
R. Bartenschlager, A. Kaul, and S. Sparacio, Antivir. Res. 60, 91 (2003).
M. Robinson, Y. Tian, W. E. Delaney, et al., Proc. Natl. Acad. Sci. USA 108, 10290 (2011).
R. A. Fridell, D. Qiu, L. Valera, et al., J. Virol. 85, 7312 (2011).
J. A. Lemm, D. O’Boyle, M. Liu, et al., J. Virol. 84, 482 (2010).
Y. He, M. S. King, D. J. Kempf, et al., Antimicrob. Agents Chemother. 52, 1101 (2008).
T. Verbinnen, H. Van Marck, I. Vandenbroucke, et al., J. Virol. 84, 11124 (2010).
T. Verbinnen, T. Jacobs, L. Vijgen, et al., J. Antimicrob. Chemother. 67, 2327 (2012).
J. E. Mathy, S. Ma, T. Compton, and K. Lin, Antimicrob. Agents Chemother. 52, 3267 (2008).
A. M. Lam, C. Espiritu, E. Murakami, et al., Antimicrob. Agents Chemother. 55, 2566 (2011).
S. Ali, V. Leveque, S. Le Pogam, et al., Antimicrob. Agents Chemother. 52, 4356 (2008).
D. Moradpour, F. Penin, and C. M. Rice, Nat. Rev. Microbiol. 5, 453 (2007).
Z. Liu, F. Yang, J. M. Robotham, J. Virol. 83, 6554 (2009).
K. L. Berger, J. D. Cooper, N. S. Heaton, et al., Proc. Natl. Acad. Sci. USA 106, 7577 (2009).
K. Lin, R. B. Perni, A. D. Kwong, and C. Lin, Antimicrob.Agents Chemother. 50, 1813 (2006).
S. J. Matthews and J. W. Lancaster, Clin. Ther. 34, 1857 (2012).
B. A. Malcolm, R. Liu, F. Lahser, et al., Antimicrob.Agents Chemother. 50, 1013 (2006).
M. P. Manns, A. A. Markova, B. Calle Serrano, and M. Cornberg, Liver Int. 32(Suppl 1), 27 (2012).
F. Habersetzer, C. Leboeuf, M. Doffoël, and T. F. Baumert, Pharmgenomics Pers. Med. 5, 125 (2012).
X. Tong, A. Arasappan, F. Bennett, et al., Antimicrob. Agents Chemother. 54, 2365 (2010).
D. M. Hotho, J. de Bruijne, M. Spaan, et al., J. Viral Hepat. 20, e78 (2013).
E. Herrmann, S. Zeuzem, C. Sarrazin, et al., Antivir.Ther. 11, 371 (2006).
M. Reiser, H. Hinrichsen, Y. Benhamou, et al., Hepatology 41, 832 (2005).
S. D. Seiwert, S. W. Andrews, Y. Jiang, et al., Antimicrob. Agents Chemother. 2, 4432 (2008).
S. R. Lim, X. Qin, S. Susser, et al., Antimicrob. Agents Chemother. 56, 271 (2012).
N. Forestier, D. Larrey, D. Guyader, et al., J. Hepatol. 54, 1130 (2011).
P. Halfon and S. Locarnini, J. Hepatol. 55, 192 (2011).
E. Foy, K. Li, R. Sumpter Jr., et al., Proc. Natl. Acad. Sci. USA 102, 2986 (2005).
L. Lu, T. J. Pilot-Matias, K. D. Stewart, et al., Antimicrob. Agents Chemother. 48, 2260 (2004).
C. Lin, C. A. Gates, B. G. Rao, et al., J. Biol. Chem. 280, 36784 (2005).
C. Lin, K. Lin, Y. P. Luong, et al., J. Biol. Chem. 279, 17508 (2004).
M. Berenguer and F. X. Lorez-Labrador, Virus Adapt. Treatm. 3, 7 (2011).
X. Tong, R. Chase, A. Skelton, et al., Antiviral Res. 70, 28 (2006).
X. Tong, S. Bogen, R. Chase, et al., Antiviral Res. 77, 177 (2008).
M. Cubero, J. I. Esteban, T. Otero, et al., Virology 370, 237 (2008).
T. Kuntzen, J. Timm, A. Berical, et al., Hepatology 48, 1769 (2008).
D. J. Bartels, Y. Zhou, E. Z. Zhang, et al., J. Infect. Dis. 198, 800 (2008).
J. Guedj, H. Dahari, L. Rong, et al., Proc. Natl. Acad. Sci. USA 110, 3991 (2013).
L. Rong, R. M. Ribeiro, and A. S. Perelson, Bull. Math. Biol. 74, 1789 (2012).
L. Rong, J. Guedj, H. Dahari, et al., PLoS Comput. Biology. 9, e1002959 (2013).
L. Rong, H. Dahari, R. M. Ribeiro, and A. S. Perelson, Sci. Transl. Med. 2, 30ra32 (2010).
B. S. Adiwijaya, E. Herrmann, B. Hare, et al., PLoSComput. Biol. 6, e1000745 (2010).
H. Dahari, R. M. Ribeiro, C. M. Rice, and A. S. Perelson, J. Virol. 81, 750 (2007).
J. Nakabayashi, J. Theor. Biol. 300, 110 (2012).
E. L. Mishchenko, K. D. Bezmaternykh, V. A. Likhoshvai, et al., J. Bioinform. Comput. Biol. 5, 593 (2007).
K. L. Berger and G. Randall, Commun. Integr. Biol. 2, 471 (2009).
E. L. Mishchenko, N. V. Ivanisenko, I. R. Akberdin, et al., Vavilov. Zh. Genet. Selekts. 16, 339 (2012).
N. Appel, U. Herian, and R. Bartenschlager, J. Virol. 79, 896 (2005).
X. Tong and B. A. Malcolm, Virus. Res. 115, 122 (2006).
D. Quinkert, R. Bartenschlager, and V. Lohmann, J. Virol. 79, 13594 (2005).
D. Egger, B. Wölk, R. Gosert, et al., J. Virol. 76, 5974 (2002).
J. Aligo, S. Jia, D. Manna, and K. V. Konan, Virology 393, 68 (2009).
S. Reiss, I. Rebhan, P. Backes, et al., Cell Host Microbe 9, 32 (2011).
M. V. Flores, J. Strawbridge, G. Ciaramella, and R. Corbau, Biochim. Biophys. Acta 1794, 1441 (2009).
M. Komorowski, M. J. Costa, D. A. Rand, and M. P. Stumpf, Proc. Natl. Acad. Sci. USA 108, 8645 (2011).
T. Pietschmann, V. Lohmann, G. Rutter, et al., J. Virol. 75, 1252 (2001).
Y. Li, T. Masaki, D. Yamane, et al., Proc. Natl. Acad.Sci. USA 110, 1881 (2013).
C. Lin, B. M. Pragai, A. Grakoui, et al., J. Virol. 68, 8147 (1994).
K. Kozlov and A. Samsonov, J. Supercomputing 57, 172 (2011).
K. Kozlov, S. Surkova, E. Myasnikova, et al., PLoS Comput. Biology 8, e1002635 (2012).
R. Storn and K. Price, Technical Report TR-95-012. ICSI (1995).
B. Wölk, B. Büchele, D. Moradpour, and C. M. Rice, J. Virol. 82, 10519 (2008).
D. M. Jones, A. H. Patel, P. Targett-Adams, and J. McLauchlan, J. Virol. 83, 2163 (2009).
Author information
Authors and Affiliations
Corresponding author
Additional information
Original Russian Text © N.V. Ivanisenko, E.L. Mishchenko, I.R. Akberdin, P.S. Demenkov, V.A. Likhoshvai, K.N. Kozlov, D.I. Todorov, M.G. Samsonova, A.M. Samsonov, N.A. Kolchanov, V.A. Ivanisenko, 2013, published in Biofizika, 2013, Vol. 58, No. 5, pp. 758–774.
Editor’s Note: I certify that this is a closest equivalent of the original publication with all its factual statements and terminology, phrasing and style; English title and Abstract provided by authors. A.G.
Rights and permissions
About this article
Cite this article
Ivanisenko, N.V., Mishchenko, E.L., Akberdin, I.R. et al. Replication of the subgenomic hepatitis C virus replicon in the presence of the NS3 protease inhibitors: a stochastic model. BIOPHYSICS 58, 592–606 (2013). https://doi.org/10.1134/S0006350913050059
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S0006350913050059